Aerovate Therapeutics is a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Co.'s initial focus is on developing AV-101, its dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. AV-101, delivered using a dry powder inhaler, is designed to provide lung concentrations at or above those observed with the oral dose while limiting systemic levels of the drug. We show 12 historical shares outstanding datapoints in our AVTE shares outstanding history coverage, used to compute AVTE market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing AVTE market cap history over the course of time is important for investors
interested in comparing AVTE's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of AVTE versus a peer is one thing; comparing
AVTE market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like AVTE can fluctuate over the course of history.
With this page we aim to empower investors researching AVTE by allowing them to research the AVTE market cap history. |
Free AVTE Email Alerts:
Video: The Importance of Market Cap
